{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:18:25Z","timestamp":1794345505888,"version":"4.9.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clinsp.2024.100329","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T11:52:48Z","timestamp":1707306768000},"page":"100329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5924-0600","authenticated-orcid":false,"given":"Yufang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9589-1943","authenticated-orcid":false,"given":"Jian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4927-011X","authenticated-orcid":false,"given":"Qianqian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9856-5866","authenticated-orcid":false,"given":"Yu","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3537-4992","authenticated-orcid":false,"given":"Yichi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0485-0430","authenticated-orcid":false,"given":"Meihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.clinsp.2024.100329_bib0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.clinsp.2024.100329_bib0002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41582-019-0220-2","article-title":"Genetic and molecular epidemiology of adult diffuse glioma","volume":"15","author":"Molinaro","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.clinsp.2024.100329_bib0003","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a society for neuro-oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100329_bib0004","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/ijms22041831","article-title":"Receptor tyrosine kinase signaling and targeting in glioblastoma multiforme","volume":"22","author":"Tilak","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.clinsp.2024.100329_bib0005","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","article-title":"Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clinsp.2024.100329_bib0006","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.clinsp.2024.100329_bib0007","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/cells8070715","article-title":"Fibroblast growth factor receptor functions in glioblastoma","volume":"8","author":"Jimenez-Pascual","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.clinsp.2024.100329_bib0008","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clinsp.2024.100329_bib0009","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinsp.2024.100329_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11060-022-04144-y","article-title":"Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab","volume":"160","author":"Lu","year":"2022","journal-title":"J Neurooncol"},{"issue":"21","key":"10.1016\/j.clinsp.2024.100329_bib0011","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100329_bib0012","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clinsp.2024.100329_bib0013","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.clinsp.2024.100329_bib0014","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593224000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593224000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T04:21:13Z","timestamp":1735791673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593224000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":14,"alternative-id":["S1807593224000061"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2024.100329","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2024.100329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100329"}}